cnbc.com / .cnbc-com-health-care / Page 3

Insurers have incomplete data on medical costs in the first quarter due to a lag in claims processing, which sets up the second quarter as the real test.

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

A common side effect of many GLP-1 drugs is hair loss. It's creating a formerly untapped but growing market for hair treatment products.

Our rationale for owning Cardinal Health remains intact.

Means' nomination had stalled in the Senate over concerns about her controversial stances on vaccines, birth control, pesticides and psychedelics.

Eli Lilly entered Thursday well off its highs. A blowout quarter shows the market got this one wrong.

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.

Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.